Statin therapy in people with diabetes and high-risk patients

Hospital Medicine

Volumn 64, Issue 1, 2003, Pages 16-19

  Wierzbicki, Anthony S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CLOFIBRATE; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FOLIC ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY RISK; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; SECONDARY PREVENTION; ARTERIOSCLEROSIS; BLOOD; DIABETIC ANGIOPATHY; HYPERLIPIDEMIA; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; CHOLESTEROL, LDL; CLINICAL TRIALS; DIABETIC ANGIOPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; RISK FACTORS;

EID: 0037974660     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2003.64.1.1838     Document Type: Conference Paper

References (19)

1. Athyros VG, Papageorgiou AA, Mercouris BR et al (2002) Treatment with Atorvastatin to the National Cholesterol Educational Program Goals versus Usual Care in Secondary Coronary Heart Disease Prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18: 220-9
2. Cholesterol and Recurrent Events Trial investigators (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-9
3. Colhoun HM, Thomason MJ, Mackness MI et al (2002) Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 19: 201-11
4. Department of Health (2000) National Service Framework for Coronary Heart Disease. The Stationery Office, London
5. Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-22
6. Evans JM, Wang J, Morris AD (2002) Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 324: 939-42
7. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG (2001) Effects of atorvastatin vs fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution and hemorheological parameters in type 2 diabetes mellitus with mixed hyperlipidemia. Am J Cardiol 87: 44-8
8. Grundy SM (1997) Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 95: 1-4
9. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ (2002) Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163: 287-96
10. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-34
11. Laasko M (1995) Epidemiology of diabetic dyslipidaemia. Diabetes Rev 3: 463-524
12. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349-57
13. MRC/BHF Heart Protection Study investigators (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22
14. Pyorala K, Pedersen TR, Kjekshus J et al (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20: 614-20
15. Rubins HB, Robins SJ, Collins D et al (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410-18
16. Sacks FM, Tonkin AM, Craven T et al (2002a) Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 105: 1424-8
17. Sacks FM and Expert Group on HDL Cholesterol (2002b) The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90: 139-43
18. Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333: 1301-7
19. Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 101: 671-9